Life-long therapy with tyrosine kinase inhibitors (TKIs) is still the consensus treatment for patients with chronic myeloid leukemia (CML), but researchers are examining the feasibility of discontinuing therapy in select individuals. The latest study on this approach, known as the A-STIM (According to Stop Imatinib) trial, suggests that patients should be evaluated for loss of major molecular response (MMR). This could be used as a criterion for resuming therapy.
http://www.medscape....warticle/818862
